KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

A Phase 3, Randomized, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Neu-BoNT/A in Treatment of Primary Axillary Hyperhidrosis.

Dong Geon Lee, Jung Eun Kim, Woo Shun Lee, Moon-Bum Kim, Chang-Hun Huh, Yang Won Lee, Gwang Seong Choi, Jee-Bum Lee, Dong Soo Yu, Min Kyung Shin, Mi Ryung Roh, Hyo Hyun Ahn, Won-Serk Kim, Jong Hee Lee, Kui Young Park, Jin Park, Weon Ju Lee, Mi Youn Park, Hoon Kang

Aesthetic Plast Surg 46(3) 1400-1406

PMID35132458
PMCID-
DOI10.1007/s00266-021-02715-4
发表日期2022-02-08
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Botulinum toxin type A is widely used to treat primary axillary hyperhidrosis and has proven to be an effective and safe approach. Onabotulinumtoxin A was approved by the FDA as a treatment for primary axillary hyperhidrosis. This study aimed to evaluate the efficacy and safety of Neu-BoNT/A in subjects diagnosed with primary axillary hyperhidrosis. METHODS: The Hyperhidrosis Disease Severity Scale, gravimetric measurement of sweat, and Global Assessment Scale were analyzed at weeks 4, 8, 12, and 16 to determine the effect of treatment. Adverse events, physical examination, and vital signs were monitored. RESULTS: Subjects treated with Neu-BoNT/A showed statistically significant improvement by all 3 methods at weeks 4, 8, 12, and 16 (P value = 0.00). There were no severe adverse events or significant changes in vital signs, physical examination, or laboratory tests. CONCLUSION: Neu-BoNT/A can be effectively and safely used for primary axillary hyperhidrosis. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。